Kichang Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kichang Han has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
- Man Deuk Kim
Department of Radiology and Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
29 shared publications - Gyoung Min Kim
Department of Radiology, Yonsei University College of Medicine, Seoul, Korea
27 shared publications - Joon Ho Kwon
Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, Korea
27 shared publications - Jong Yun Won
Department of Radiology and Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
25 shared publications Do Yun Lee
Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, 50 Yonsei-ro Seodaemun-gu, Seoul 120-752, Korea
12 shared publicationsGi-Young Ko
Department of Radiology and Research Institute of Radiology, University of Ulsan, College of Medicine, Asan Medical Center, 86, Asanbyeongwon-gil, Songpa-gu, Seoul, 138-736, South Korea
7 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Korean Society of Interventional Radiology in Korean Journal of Interventional Radiology
- Vol. 31  (2) , 156-163
Clinical Efficacy and Patency of Stents for Malignant Iliocaval Venous Occlusion
Purpose: This study aimed to evaluate the clinical efficacy and patency of stents placed for symptomatic iliac vein or IVC obstruction caused by malignant tumors.Materials and Methods: A total of 34 consecutive patients with malignant iliac vein or IVC obstruction underwent stent placement. We reviewed their electronic medical records, pre- and post-procedural CT scans, and angiograms retrospectively, and evaluated technical success, clinical success, and patient-based and vessel-based reocclusion rates confirmed by follow-up cross-sectional images. The reocclusion rate difference between IVC and iliac stents was also assessed.Results: All patients complained of leg and/or trunk edema. The stents were placed in the following locations: IVC (n = 9); iliac veins (n = 19); and both IVC and iliac veins (n = 6). Technical success rate was 100% and the clinical success rate was 87.5% during hospitalization. Cross-sectional area of the affected thigh was significantly decreased after stent placement (mean 11.7%, p = 0.003). The median follow-up period was 65 days (Q1–Q3, 28.5–227.3; IQR, 198.8). The patient-based reocclusion rate was 42.8%. The vessel- based reocclusion rates for IVC (12.5%) tended to be lower than those of iliac veins (45.0%), though the difference was not statistically significant (p = 0.194).Conclusion: Stent insertion for iliac vein or IVC obstruction secondary to malignancy is technically feasible and can help to improve patients’ symptoms. IVC stents tend to achieve a higher rate of patency than iliac vein stents.
- 30 September 2026
- Published by Korean Society of Interventional Radiology in Korean Journal of Interventional Radiology
- Vol. 31  (2) , 156-163
Open AccessClinical Efficacy and Patency of Stents for Malignant Iliocaval Venous Occlusion
Purpose: This study aimed to evaluate the clinical efficacy and patency of stents placed for symptomatic iliac vein or IVC obstruction caused by malignant tumors.Materials and Methods: A total of 34 consecutive patients with malignant iliac vein or IVC obstruction underwent stent placement. We reviewed their electronic medical records, pre- and post-procedural CT scans, and angiograms retrospectively, and evaluated technical success, clinical success, and patient-based and vessel-based reocclusion rates confirmed by follow-up cross-sectional images. The reocclusion rate difference between IVC and iliac stents was also assessed.Results: All patients complained of leg and/or trunk edema. The stents were placed in the following locations: IVC (n = 9); iliac veins (n = 19); and both IVC and iliac veins (n = 6). Technical success rate was 100% and the clinical success rate was 87.5% during hospitalization. Cross-sectional area of the affected thigh was significantly decreased after stent placement (mean 11.7%, p = 0.003). The median follow-up period was 65 days (Q1–Q3, 28.5–227.3; IQR, 198.8). The patient-based reocclusion rate was 42.8%. The vessel- based reocclusion rates for IVC (12.5%) tended to be lower than those of iliac veins (45.0%), though the difference was not statistically significant (p = 0.194).Conclusion: Stent insertion for iliac vein or IVC obstruction secondary to malignancy is technically feasible and can help to improve patients’ symptoms. IVC stents tend to achieve a higher rate of patency than iliac vein stents.
- Open Access
- 11 May 2026
- Published by Korean Society of Interventional Radiology in Korean Journal of Interventional Radiology
- Vol. 31  (2) , 92-102
Drug-Coated Balloon Angioplasty for Dysfunctional Hemodialysis Access: An Update
Korean Journal of Interventional Radiology
- 11 May 2026
- Published by Korean Society of Interventional Radiology in Korean Journal of Interventional Radiology
- Vol. 31  (2) , 92-102
Open AccessDrug-Coated Balloon Angioplasty for Dysfunctional Hemodialysis Access: An Update
Korean Journal of Interventional Radiology
- Open Access
- 1 January 2026
- Published by XMLink in Korean Journal of Radiology
- Vol. 27  (2) , 152-160
Prospective Evaluation of Irreversible Electroporation With Clustered Electrodes as a Novel Palliative Approach for Locally Advanced Pancreatic Cancer
This study aimed to evaluate the feasibility, safety, and oncologic outcomes of irreversible electroporation (IRE) using a clustered electrode in patients with locally advanced pancreatic cancer (LAPC). In this single-center prospective cohort study, 13 patients with LAPC (median age, 60 years; range, 48–78 years) underwent clustered electrode IRE between September 2022 and September 2024. Patient characteristics, procedural details, and clinical outcomes were recorded. Endpoints included technical success, procedure-related complications, overall survival (OS), and progression-free survival (PFS). Tumors were located in the pancreatic head in four patients (30.8%) and in the body/tail in nine (69.2%). The median tumor size was 2.4 cm (1.5–4.0 cm), and vascular invasion was present in all patients. Technical success was achieved in all patients. Intraoperative IRE was performed in 11 (84.6%) patients, and 2 (15.4%) patients underwent percutaneous IRE. Gastrointestinal bleeding events as major complications occurred in two patients (15.4%) and, both were successfully controlled by embolization. No 60-day mortality was observed. At a median follow-up of 24.5 months (range, 9.9–33.4 months) after IRE, median OS and PFS from IRE were 20.1 and 14.5 months, respectively. IRE using clustered electrodes for LAPC appears to be a feasible therapeutic approach, offering reliable technical success and acceptable safety. Survival outcomes are encouraging; however, larger, controlled studies are required.
- 1 January 2026
- Published by XMLink in Korean Journal of Radiology
- Vol. 27  (2) , 152-160
Open AccessProspective Evaluation of Irreversible Electroporation With Clustered Electrodes as a Novel Palliative Approach for Locally Advanced Pancreatic Cancer
This study aimed to evaluate the feasibility, safety, and oncologic outcomes of irreversible electroporation (IRE) using a clustered electrode in patients with locally advanced pancreatic cancer (LAPC). In this single-center prospective cohort study, 13 patients with LAPC (median age, 60 years; range, 48–78 years) underwent clustered electrode IRE between September 2022 and September 2024. Patient characteristics, procedural details, and clinical outcomes were recorded. Endpoints included technical success, procedure-related complications, overall survival (OS), and progression-free survival (PFS). Tumors were located in the pancreatic head in four patients (30.8%) and in the body/tail in nine (69.2%). The median tumor size was 2.4 cm (1.5–4.0 cm), and vascular invasion was present in all patients. Technical success was achieved in all patients. Intraoperative IRE was performed in 11 (84.6%) patients, and 2 (15.4%) patients underwent percutaneous IRE. Gastrointestinal bleeding events as major complications occurred in two patients (15.4%) and, both were successfully controlled by embolization. No 60-day mortality was observed. At a median follow-up of 24.5 months (range, 9.9–33.4 months) after IRE, median OS and PFS from IRE were 20.1 and 14.5 months, respectively. IRE using clustered electrodes for LAPC appears to be a feasible therapeutic approach, offering reliable technical success and acceptable safety. Survival outcomes are encouraging; however, larger, controlled studies are required.
- 13 May 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 36  (8) , 1321-1329
Safety and Patency of Bare-Metal Stent versus Stent Graft Placement in Patients with Extrahepatic Portal Vein Occlusion from Pancreatic and Biliary Malignancies
- 13 May 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 36  (8) , 1321-1329
Safety and Patency of Bare-Metal Stent versus Stent Graft Placement in Patients with Extrahepatic Portal Vein Occlusion from Pancreatic and Biliary Malignancies
- 5 February 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 82  (6) , 1498-1511
Coil or plug-assisted retrograde transvenous obliteration (CARTO/PARTO) for treating portal hypertensive variceal bleeding: A multicenter, real-world 10-year retrospective study
Background and Aims: Coil-assisted retrograde transvenous obliteration (CARTO) and plug-assisted retrograde transvenous obliteration (PARTO) are well-accepted treatments for gastric variceal bleeding. However, long-term (>2 y) clinical outcomes have yet to be studied. In this study, we investigated long-term clinical outcomes, including overall survival (OS) in 10 years. Approach and Results: We performed a multinational, multicenter, retrospective study of CARTO/PARTO in gastric varices treatments between May 2012 and July 2024. The primary study outcomes were a long-term OS and prognostic factors of CARTO/PARTO. The secondary outcomes were long-term clinical/technical success, complications, and clinical changes including portal hypertensive symptoms. A total of 311 patients (41% female; 69% CARTO) from 13 centers in 5 countries were included. The cumulative 1-, 3-, 5-, 7-, and 10-year OS rates were 98%, 80%, 68%, 52%, and 33%, respectively, with a median OS of 99 months. Prophylactic CARTO/PARTO showed a better OS than CARTO/PARTO for active bleeding ( p =0.00035). The independent prognostic factors of OS were having high pre-MELD, concurrent HCC, treating GOV2, history of esophageal variceal bleeding, high pre-TBili, and ammonia levels. Notably, a high pre-MELD score >27 had a significantly higher mortality rate (92.6%) than a lower pre-MELD score ( p <0.001). The overall cumulative 1-, 3-, 5-, 7-, and 10-year recurrent gastric varices bleeding rates were 0.9%, 3.2%, 4.0%, 4.5%, and 5.4%, respectively. The overall technical and clinical success rates were 96.5% and 95.3%, respectively, with a 4.5% major complication rate over 10 years. Conclusions: CARTO and PARTO have excellent long-term survival and clinical outcomes. However, these are negatively affected by high MELD scores, concomitant HCC, and coexisting esophageal varices.
- 5 February 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 82  (6) , 1498-1511
Coil or plug-assisted retrograde transvenous obliteration (CARTO/PARTO) for treating portal hypertensive variceal bleeding: A multicenter, real-world 10-year retrospective study
Background and Aims: Coil-assisted retrograde transvenous obliteration (CARTO) and plug-assisted retrograde transvenous obliteration (PARTO) are well-accepted treatments for gastric variceal bleeding. However, long-term (>2 y) clinical outcomes have yet to be studied. In this study, we investigated long-term clinical outcomes, including overall survival (OS) in 10 years. Approach and Results: We performed a multinational, multicenter, retrospective study of CARTO/PARTO in gastric varices treatments between May 2012 and July 2024. The primary study outcomes were a long-term OS and prognostic factors of CARTO/PARTO. The secondary outcomes were long-term clinical/technical success, complications, and clinical changes including portal hypertensive symptoms. A total of 311 patients (41% female; 69% CARTO) from 13 centers in 5 countries were included. The cumulative 1-, 3-, 5-, 7-, and 10-year OS rates were 98%, 80%, 68%, 52%, and 33%, respectively, with a median OS of 99 months. Prophylactic CARTO/PARTO showed a better OS than CARTO/PARTO for active bleeding ( p =0.00035). The independent prognostic factors of OS were having high pre-MELD, concurrent HCC, treating GOV2, history of esophageal variceal bleeding, high pre-TBili, and ammonia levels. Notably, a high pre-MELD score >27 had a significantly higher mortality rate (92.6%) than a lower pre-MELD score ( p <0.001). The overall cumulative 1-, 3-, 5-, 7-, and 10-year recurrent gastric varices bleeding rates were 0.9%, 3.2%, 4.0%, 4.5%, and 5.4%, respectively. The overall technical and clinical success rates were 96.5% and 95.3%, respectively, with a 4.5% major complication rate over 10 years. Conclusions: CARTO and PARTO have excellent long-term survival and clinical outcomes. However, these are negatively affected by high MELD scores, concomitant HCC, and coexisting esophageal varices.
- 4 October 2024
- Published by Elsevier in European Journal of Radiology
- Vol. 181, 111773
Factors affecting the technical outcome of catheter-directed sclerotherapy for ovarian endometriomas
- 4 October 2024
- Published by Elsevier in European Journal of Radiology
- Vol. 181, 111773
Factors affecting the technical outcome of catheter-directed sclerotherapy for ovarian endometriomas
- 1 September 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 312  (3) , e231525
Resorbable Microspheres versus Trisacryl Gelatin Microspheres for Uterine Artery Embolization: A Randomized Controlled Trial
When used for uterine artery embolization for symptomatic fibroids, resorbable microspheres showed no evidence of a difference from trisacryl gelatin microspheres in terms of therapeutic effectiveness or postprocedural pain scores.
- 1 September 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 312  (3) , e231525
Resorbable Microspheres versus Trisacryl Gelatin Microspheres for Uterine Artery Embolization: A Randomized Controlled Trial
When used for uterine artery embolization for symptomatic fibroids, resorbable microspheres showed no evidence of a difference from trisacryl gelatin microspheres in terms of therapeutic effectiveness or postprocedural pain scores.
- Open Access
- 1 January 2024
- Published by XMLink in Korean Journal of Radiology
- Vol. 25  (1) , 55-61
Thoracic Duct Embolization for Treatment of Chyle Leakage After Thyroidectomy and Neck Dissection
Moon S, et al. Korean J Radiol. 2024 Jan;25(1):55-61. https://doi.org/10.3348/kjr.2023.0658
- 1 January 2024
- Published by XMLink in Korean Journal of Radiology
- Vol. 25  (1) , 55-61
Open AccessThoracic Duct Embolization for Treatment of Chyle Leakage After Thyroidectomy and Neck Dissection
Moon S, et al. Korean J Radiol. 2024 Jan;25(1):55-61. https://doi.org/10.3348/kjr.2023.0658
- 4 January 2023
- Published by SAGE Publications in Acta Radiologica
- Vol. 65  (3) , 302-306
Efficacy of intra-arterial lidocaine administration on pain and inflammatory response after uterine artery embolization for symptomatic fibroids
Background: There have been conflicting outcomes regarding the use of lidocaine to reduce pain after uterine artery embolization (UAE). Purpose: To investigate the efficacy of intra-arterial lidocaine injection for pain and inflammatory response control within 24 h of UAE for symptomatic uterine fibroids. Material and Methods: Of 1530 patients who underwent UAE for uterine fibroids in 2007–2021, 5 mL of 1% lidocaine was injected into each uterine artery immediately after UAE in 23 patients. A disease-matched control group (n = 23) who did not receive intra-arterial lidocaine was generated from the same registry. The pain score, white blood cell (WBC) count, C-reactive protein (CRP), neutrophil/lymphocyte ratio (NLR), and fentanyl consumption were compared before and after UAE. Complete infarction of the dominant fibroid was assessed using magnetic resonance imaging. Results: Significantly lower WBC count, CRP level, and NLR were noted 24 h after UAE in the lidocaine group. No statistically significant difference was noted in the pain score between groups at 0–24 h. The cumulative fentanyl dose administered during the first 24 h after UAE was not significantly different. After embolization, fibroid-related symptoms resolved in all patients. No significant difference was observed in the rate of complete infarction of the dominant fibroid. Conclusion: Lidocaine administration immediately after UAE resulted in a significant reduction in the inflammatory response. However, such a difference in the inflammatory reaction did not contribute to significant reductions in pain scores or fentanyl consumption.
- 4 January 2023
- Published by SAGE Publications in Acta Radiologica
- Vol. 65  (3) , 302-306
Efficacy of intra-arterial lidocaine administration on pain and inflammatory response after uterine artery embolization for symptomatic fibroids
Background: There have been conflicting outcomes regarding the use of lidocaine to reduce pain after uterine artery embolization (UAE). Purpose: To investigate the efficacy of intra-arterial lidocaine injection for pain and inflammatory response control within 24 h of UAE for symptomatic uterine fibroids. Material and Methods: Of 1530 patients who underwent UAE for uterine fibroids in 2007–2021, 5 mL of 1% lidocaine was injected into each uterine artery immediately after UAE in 23 patients. A disease-matched control group (n = 23) who did not receive intra-arterial lidocaine was generated from the same registry. The pain score, white blood cell (WBC) count, C-reactive protein (CRP), neutrophil/lymphocyte ratio (NLR), and fentanyl consumption were compared before and after UAE. Complete infarction of the dominant fibroid was assessed using magnetic resonance imaging. Results: Significantly lower WBC count, CRP level, and NLR were noted 24 h after UAE in the lidocaine group. No statistically significant difference was noted in the pain score between groups at 0–24 h. The cumulative fentanyl dose administered during the first 24 h after UAE was not significantly different. After embolization, fibroid-related symptoms resolved in all patients. No significant difference was observed in the rate of complete infarction of the dominant fibroid. Conclusion: Lidocaine administration immediately after UAE resulted in a significant reduction in the inflammatory response. However, such a difference in the inflammatory reaction did not contribute to significant reductions in pain scores or fentanyl consumption.
- Open Access
- 1 January 2023
- Published by XMLink in Korean Journal of Radiology
- Vol. 24  (12) , 1241-1248
Feasibility of Percutaneous Pancreatic Stent Placement in Postoperative Pancreaticojejunostomy Stenosis
Park J, et al. Korean J Radiol. 2023 Dec;24(12):1241-1248. https://doi.org/10.3348/kjr.2023.0459
- 1 January 2023
- Published by XMLink in Korean Journal of Radiology
- Vol. 24  (12) , 1241-1248
Open AccessFeasibility of Percutaneous Pancreatic Stent Placement in Postoperative Pancreaticojejunostomy Stenosis
Park J, et al. Korean J Radiol. 2023 Dec;24(12):1241-1248. https://doi.org/10.3348/kjr.2023.0459